Marc Bickle
Marc Bickle obtained his PhD at the Biozentrum in Basel, Switzerland, studying the immunosuppressive drug Rapamycin using yeast. He then went to the LMB in Cambridge, UK, to study behavior in C. elegans. He then participated in the creation of Aptanomics, a drug discovery Biotech in Lyon, France. He is currently heading the group of kinetic HCS at the MPG-MPI in Dresden, Germany, developing secondary RNAi and chemical screens.
